Johnson & Johnson (NYSE:JNJ) Shares Sold by Altus Wealth Group LLC

Altus Wealth Group LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,416 shares of the company’s stock after selling 124 shares during the period. Altus Wealth Group LLC’s holdings in Johnson & Johnson were worth $875,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. DORCHESTER WEALTH MANAGEMENT Co lifted its stake in Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P lifted its stake in Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares during the last quarter. IFM Investors Pty Ltd lifted its stake in Johnson & Johnson by 20.1% in the first quarter. IFM Investors Pty Ltd now owns 418,999 shares of the company’s stock worth $74,259,000 after acquiring an additional 70,221 shares during the last quarter. Essex LLC lifted its stake in Johnson & Johnson by 3.7% in the first quarter. Essex LLC now owns 32,274 shares of the company’s stock worth $5,720,000 after acquiring an additional 1,146 shares during the last quarter. Finally, PRW Wealth Management LLC lifted its stake in Johnson & Johnson by 8.8% in the first quarter. PRW Wealth Management LLC now owns 2,595 shares of the company’s stock worth $459,000 after acquiring an additional 210 shares during the last quarter. 68.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 118,795 shares of company stock valued at $20,230,174. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $176.20 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The stock has a market capitalization of $460.67 billion, a P/E ratio of 24.54, a P/E/G ratio of 3.44 and a beta of 0.57. The company’s fifty day moving average is $167.84 and its two-hundred day moving average is $171.40. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.60 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson announced that its board has approved a stock repurchase program on Wednesday, September 14th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date is Monday, November 21st. This represents a $4.52 annualized dividend and a yield of 2.57%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Analyst Ratings Changes

Several brokerages have recently weighed in on JNJ. Credit Suisse Group began coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “neutral” rating and a $170.00 price objective for the company. StockNews.com began coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Bank of America reduced their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 19th. Finally, Atlantic Securities reduced their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.